MX2007014403A - Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. - Google Patents

Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.

Info

Publication number
MX2007014403A
MX2007014403A MX2007014403A MX2007014403A MX2007014403A MX 2007014403 A MX2007014403 A MX 2007014403A MX 2007014403 A MX2007014403 A MX 2007014403A MX 2007014403 A MX2007014403 A MX 2007014403A MX 2007014403 A MX2007014403 A MX 2007014403A
Authority
MX
Mexico
Prior art keywords
sub
formula
allosteric modulators
positive allosteric
0xadiaz0l
Prior art date
Application number
MX2007014403A
Other languages
English (en)
Inventor
Jean-Philippe Rocher
Stefania Gagliardi
Emmanuel Le Poul
Giovanni Palombi
Lain Lingard
Sonia Maria Poli
Original Assignee
Addex Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharmaceuticals Sa filed Critical Addex Pharmaceuticals Sa
Publication of MX2007014403A publication Critical patent/MX2007014403A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)

Abstract

La presente invencion proporciona nuevos compuestos de la formula (I): (ver formula (I)) como moduladores aloestericos positivos de los receptores metabotropicos - subtipo 5 ("mGluR5"), los cuales son utiles para el tratamiento o la prevencion de trastornos del sistema nervioso central, tales como, por ejemplo, declinacion cognoscitiva, sintomas tanto positivos como negativos de la esquizofrenia, asi como otros trastornos del sistema nerviosos central o periferico en donde este involucrado el subtipo mGluR5 del receptor de glutamato metabotropico. La invencion tambien se refiere a compuestos y composiciones farmaceuticas para la prevencion o el tratamiento de estas enfermedades en donde esta involucrado el mGluR5. W representa un anillo de cicloalquilo (de 4 a 7 atomos de carbono), hetero-cicloalquilo (de 3 a 7 atomos de carbono), hetero-cicloalquilo.
MX2007014403A 2005-05-18 2006-05-17 Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. MX2007014403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510141.5A GB0510141D0 (en) 2005-05-18 2005-05-18 Novel compounds B3
PCT/IB2006/002047 WO2006123257A2 (en) 2005-05-18 2006-05-17 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
MX2007014403A true MX2007014403A (es) 2008-04-21

Family

ID=34708379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014403A MX2007014403A (es) 2005-05-18 2006-05-17 Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.

Country Status (24)

Country Link
US (1) US20090203737A1 (es)
EP (1) EP1912979B1 (es)
JP (2) JP2008540637A (es)
KR (1) KR20080014046A (es)
CN (1) CN101218234B (es)
AT (1) ATE513828T1 (es)
AU (1) AU2006248657B2 (es)
BR (1) BRPI0610059A2 (es)
CA (1) CA2608324A1 (es)
CY (1) CY1111859T1 (es)
DK (1) DK1912979T3 (es)
EA (1) EA014081B1 (es)
ES (1) ES2367663T3 (es)
GB (1) GB0510141D0 (es)
HK (1) HK1112909A1 (es)
IL (1) IL187187A0 (es)
MX (1) MX2007014403A (es)
NO (1) NO20076480L (es)
NZ (1) NZ564202A (es)
PL (1) PL1912979T3 (es)
PT (1) PT1912979E (es)
UA (1) UA92494C2 (es)
WO (1) WO2006123257A2 (es)
ZA (1) ZA200710279B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015813B1 (ru) * 2005-05-18 2011-12-30 Аддекс Фарма Са Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100317630A1 (en) * 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
JP2012524798A (ja) * 2009-04-23 2012-10-18 メルク・シャープ・エンド・ドーム・コーポレイション ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HUE038512T2 (hu) 2012-11-13 2018-10-29 Array Biopharma Inc N-pirrolidinil-, N'-pirazolil-karbamid, tiokarbamid, guanidin és cianoguanidin vegyületek mint TrkA kináz inhibitorok
HUE031557T2 (en) 2012-11-13 2017-07-28 Array Biopharma Inc Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
PL3154959T3 (pl) 2014-05-15 2019-12-31 Array Biopharma, Inc. 1-((3S,4R)-4-(3-Fluorofenylo)-1-(2-metoksyetylo)pirolidyn-3-ylo)-3-(4-metylo-3- (2- metylopirymidyn-5-ylo)-1-fenylo-1H-pirazol-5-ilo)-mocznik jako inhibitor kinazy TrkA
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド
WO2022069953A1 (en) * 2020-09-29 2022-04-07 Ranjith Siddaraj Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
WO2024059207A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University Pyrazoloether analogs as mglu5 negative allosteric modulators and methods of making and using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US3966748A (en) * 1975-05-08 1976-06-29 American Cyanamid Company Para-fluorophenyl-N-heterocyclic substituted butanes
US5338969A (en) * 1991-06-27 1994-08-16 Texas Instruments, Incorporated Unerasable programmable read-only memory
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
WO2000066578A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
ES2243337T3 (es) * 1999-12-16 2005-12-01 Schering Corporation Imidazoles sustituidos antagonistas del receptor y5 del neuropeptido y.
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
EP1300396B1 (en) * 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
PT1289955E (pt) * 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US6946476B2 (en) * 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
ATE312827T1 (de) * 2001-09-21 2005-12-15 Mitsubishi Pharma Corp 3-substituierte-4-pyrimidonderivate
EA007576B1 (ru) * 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003037862A1 (fr) * 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Derives amide, et medicaments correspondants
US6806279B2 (en) * 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
CA2495179A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
WO2004048334A1 (en) * 2002-11-26 2004-06-10 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
SI1867644T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP2295434B1 (en) * 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
BRPI0511481A (pt) * 2004-05-25 2007-12-26 Pfizer Prod Inc uso
BRPI0515851A (pt) * 2004-09-29 2008-08-12 Mitsubishi Pharma Corp composto de pirimidona
CA2584248A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
EP1809620B1 (en) * 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US7713998B2 (en) * 2004-11-10 2010-05-11 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
CN101242834A (zh) * 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
EA015813B1 (ru) * 2005-05-18 2011-12-30 Аддекс Фарма Са Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
ATE513828T1 (de) 2011-07-15
WO2006123257A2 (en) 2006-11-23
DK1912979T3 (da) 2011-08-22
AU2006248657A1 (en) 2006-11-23
WO2006123257A8 (en) 2007-03-15
EP1912979B1 (en) 2011-06-22
EA200702470A1 (ru) 2008-06-30
PT1912979E (pt) 2011-08-22
JP2008540637A (ja) 2008-11-20
BRPI0610059A2 (pt) 2010-05-25
ZA200710279B (en) 2009-03-25
CA2608324A1 (en) 2006-11-23
WO2006123257A3 (en) 2007-05-03
KR20080014046A (ko) 2008-02-13
CN101218234A (zh) 2008-07-09
JP2012184254A (ja) 2012-09-27
UA92494C2 (ru) 2010-11-10
GB0510141D0 (en) 2005-06-22
HK1112909A1 (en) 2008-09-19
CN101218234B (zh) 2011-12-14
ES2367663T3 (es) 2011-11-07
IL187187A0 (en) 2008-02-09
NZ564202A (en) 2011-04-29
US20090203737A1 (en) 2009-08-13
EA014081B1 (ru) 2010-08-30
NO20076480L (no) 2008-01-28
PL1912979T3 (pl) 2011-11-30
CY1111859T1 (el) 2015-11-04
AU2006248657B2 (en) 2012-07-19
EP1912979A2 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
MX2007014403A (es) Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
JP7482873B2 (ja) Ｉｌ－１７調節剤としてのベンズイミダゾロン誘導体及びその類似体
CA2965517C (en) Indole carboxamides compounds useful as kinase inhibitors
NO20082719L (no) Aryl-isoksazol-4-yl-oksadiazolderivater
US5696145A (en) 1-benzyl-1,3-dihydroindol-2-one derivatives, their preparation and the pharmaceutical compositions in which they are present
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
AU2018368745A1 (en) Indole Compounds and Their Use
MXPA05011670A (es) Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.
WO2015140717A9 (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
SI9200405A (en) New indole and indoldion derivatives, process and intermediates for the preparation thereof and pahrmaceutical composition comprising the same
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
AU2005286718A1 (en) Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
JP2012529476A (ja) 神経変性疾患治療における使用のためのインドールアミン誘導体および関連化合物
MX2011000021A (es) Inhibidores de proteina cinasas.
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
CA2587381A1 (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
KR20080038239A (ko) 카나비노이드 ｃｂ1 수용체의 효능제로서의(인돌-3-일)-헤테로사이클 유도체
CA3104264A1 (en) Thiadiazine derivatives
ES2628206T3 (es) Derivados de etinilo como antagonistas de los receptores metabotrópicos del glutamato
JP5753626B2 (ja) ピラゾリジン−３−オン誘導体
AU2017279905B2 (en) Anti-infective heterocyclic compounds and uses thereof
KR20090113383A (ko) 인돌 유도체
WO2008037681A8 (en) 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.

Legal Events

Date Code Title Description
FG Grant or registration